Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to l-dopa in the treatment of Parkinson's disease: A randomized, multicenter, open-label, parallel-group study

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 142-150

  Ries, Vincent ^a   Selzer, Roland ^b   Eichhorn, Tobias ^a,c   Oertel, Wolfgang H ^a   Eggert, Karla ^a   Baas, H ^d   Beikirch, E G ^d   Benecke, R ^d   Bereznai, T B ^d   Einhaupl K M ^d   Fornadi, F A ^d   Fuchs, G ^d   Gasser, T H ^d   Gemende, I ^d   Gerdes, U ^d   Glass J ^d   Henneberg, A ^d   Herting, B ^d   Hoppner J ^d   Homann, C N ^d   Kamm, C ^d   Klemm, H P ^d   Kogan, E ^d   Kuhnl N ^d   Kupsch, A ^d   Lachenmayer, L ^d   Malsch, U ^d   Oertel, W H ^d   Ott, E ^d   Petri, H ^d   Pogarell, O ^d   Rathay, B ^d   Reichmann, H ^d   Schenkel Romer A ^d   Schneider, E ^d   Schwenkenbecher, S ^d   Singer, M ^d   Sommer, H ^d   Stefan, K ^d   Trausch, B ^d   Ulm, G ^d   Werner, M ^d   Wunderlich, C ^d   Zehrden, F ^d   more..

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c Pfizer Manufacturing Austria   (Austria)

^d NONE

Author keywords

Dopamine agonists; Motor fluctuations; Parkinson's disease; Switch; Tolcapone

Indexed keywords

BROMOCRIPTINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; TOLCAPONE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; ADULT; ARTICLE; BACKACHE; BLOOD CHEMISTRY; BLOOD EXAMINATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ECG ABNORMALITY; FATIGUE; FEMALE; HALLUCINATION; HUMAN; HYPERKINESIA; INVESTIGATOR GLOBAL ASSESSMENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEX RATIO; SIDE EFFECT; SUICIDE ATTEMPT; SWEATING; THORAX PAIN; THROMBOPHLEBITIS; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

AGED; AMBULATORY CARE FACILITIES; BENSERAZIDE; BENZOPHENONES; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; DOPA DECARBOXYLASE; DOPAMINE AGONISTS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSKINESIAS; ENZYME INHIBITORS; FEASIBILITY STUDIES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953152861     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181d99d6f     Document Type: Article

References (33)

1. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17: S32-S44.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
3. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in patients with Parkinson's disease. Neurology 1994;44:913-919.
4. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21:343-353.
5. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
6. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-1760.
7. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
8. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the Bwearing-off[phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
9. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87.
10. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
11. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004;4: CD004554.
12. Koller W, Lees A, Doder M, et al. Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
13. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov Disord 1999;14:38-44.
14. Olanow CW. Tolcapone and hepatotoxic effects; Tasmar Advisory Panel. Arch Neurol 2000;57:263-267.
15. Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol 2007;30:287-294.
16. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
17. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
18. Dhawan V, Healy DG, Pal S, et al. Sleep-related problems of Parkinson's disease. Age Ageing 2006;35:220-228.
19. Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Rev Neurother 2007;7:1731-1750.
20. Möller JC, Eggert KM, Unger M, et al. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol 2008;15: S15-S23.
21. Fahn S, Elton RL; Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
22. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intrarater reliability assessment. Mov Disord 1994;9:390-394.
23. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
24. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
25. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39) : development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-357.
26. Myllylä VV, Jackson M, Larsen JP, et al. Tolcapone International Parkinson's Disease Study (TIPS) Group I. Effect and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 1997;4:333-341.
27. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.
28. Lew MF, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol 2007;30:281-286.
29. Lees AJ, Ratziu V, Tolosa E, et al. Safety and tolerability of adjunctive tolcapone in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:944-948.
30. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56:730-736.
31. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. (Pubitemid 47597592)
32. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496. (Pubitemid 29438205)
33. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.